DEC 0 8 2003 EN

Docket No.: PF-0676 USN

Certificate of Mailing

By: 12 12 21

Printed: Lisa McDill

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tang et al.

Title:

**HUMAN LIPID-ASSOCIATED PROTEINS** 

Serial No.:

09/890,549

Filing Date:

May 8, 2002

Examiner:

Kam, Chih-Min

Group Art Unit:

1653

Mail Stop Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

Docket No.: PF-0676 USN

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE CORPORATION

Date: \_\_\_\_December 4, 2003

James M. Verna, Ph.D.

Reg. No. 33,287

Direct Dial Telephone: (650) 845 -5415

Customer No.: 27904
3160 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555 Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.	
	PF-0676 USN	09/890,549	
PE DIST OF REFERENCES CITED BY APPLICANTS	Applicant(s)		
(Use several sheets if necessary)	Tang et al.		
DEC 0 8 2003 E	Filing Date	Group	
P. Company of the Com	May 8, 2002	1653	
To make the second of the seco			

			U.S.	Patent Documents				
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing I If Appro	
		<u> </u>	Foreign	n Patent Documents	<u> </u>			
		Transla						lation
		Document	Date	Country	Class	Subclass	Yes	No
	OMI	IED ARM (Tw	aluding Auth	Data Data	Dortinor	t Pages E	- \	
	1	HER ART (Including Author, Title, Date, Pertinent Pages, Etc.)  Chang, D. et al., "Characterization of transformation related genes in oral cancer cells", Oncogene 16, pp. 1921-1930 (1998)						
	2	Chen, S. et al., "Characterization of the human <i>EPLIN</i> (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms", Gene 248, pp. 69-76 (2000)						
	3	Huang, Q. et al., NCBI Database, Accession AAF67491 (GI 7688701), 04-MAY-2000						
	4	Maul, R.S. and Chang, D.D., NCBI Database, Accession AF198454 (GI 6685006), 10-JAN-2000						
	5	Maul, R.S. et al., "EPLIN regulates actin dynamics by cross-linking and stabilizing filaments, Journal of Cell Biology 160, No. 3, pp. 399-407 (2003)						
	6	Maul, R.S. and Chang, D.D., "EPLIN, Epithelial protein lost in neoplasm", Oncogene 18, pp. 7838-7841, (1999)						
	7	Yang, J. et al., NCBI Database, Accession U22818 (GI 841317), 26-JAN-1996						
	(i - i )							

Examiner	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.